The PGX2 team took part in the international forum for innovative development «Open innovations» in the session «Health Innovation in the the fight against the pandemic».

PGX2 won a grant for further development and commercialization of its innovations.

On October 20, 2020, the final of the Patent Power 2020 biomedical startup competition was held as part of the Open innovations Forum. The PGX2 project was a finalist in the competition and received a grant for intellectual property protection.

The Patent Power 2020 competition is organized by the SKOLKOVO Foundation together with Bayer with the support of the world intellectual property organization, the Eurasian patent office and the Federal Institute of industrial property. The goal of the competition is to find medical startups with a high potential for intellectual property protection.

Three winners of the competition will receive a grant from Bayer in the amount of 700,000 rubles, as well as the opportunity to present the project to Bayer's top management. The winners will be able to use mentoring support from the competition Organizers for further development of the project concept, help in finding tools for further financing and (or) commercialization, as well as submit projects to partners for consideration and get expert advice on further development of the project.

Open innovations Forum

PGX2 solution is marked on the digital health map 2020 in «Personal Genetic Solutions».

PGX2 was included in the contour of innovative solutions of the Moscow Innovation Agency.

PGX2 finished as the winner of the Biomedtech track of «Moscow Accelerator».

On September 15, 2020, Demoday was held as a part of the Biomedtech track of «Moscow Accelerator». The jury and experts of the acceleration program of the Moscow Government’s Innovation Agency evaluated 18 innovative projects, among which a technology that allows to predict and avoid risks of adverse drug reactions – «PharmacoGenomeX2».

Alla Panchenko, CBDO of PGX2 pitched the startup, mentioning current issues, technology highlights, market and business model insights.

Invitro, the largest private company on the commercial laboratory research market in Russia, invited PGX2 to launch a pilot project with a network of laboratories. PGX2 startup team also received the right to participate in the final of the Biobridge international acceleration program in Austria in 2021.

Dmitriy Fadin and Alla Panchenko
Dmitry Fadin, Director of strategic development and innovation at Invitro and Alla Panchenko, CBDO at PharmacoGenomeX2

The PGX2 team thanks the organizers and partners for a quick and intense acceleration.

PGX2 among the winners of the Biomedtech track of «Moscow Accelerator».

PGX2 startup was selected to participate in the BioMedTech track of the Moscow accelerator among 30 best startups.

The Moscow accelerator is a joint initiative of the Moscow innovation Agency and the Moscow Innovation Cluster Foundation, implemented with the support of the Moscow Department of Entrepreneurship and Innovative development.

The partners of the BioMedTech track of the acceleration program are the HIMRAR group of companies and the Invitro holding.

Personalized Therapy. DNA analysis will help you avoid undesired drug reactions. Continue reading at Kommersant.

CEO Interview. How much does it cost to decode the human genome and why do you need it. Continue reading at RBK.

The Future of Science: inventions and developments of participants of the "Science" contest "Leaders of Russia" 2020. Continue reading at Science & Life.

PGX2 startup became a resident of the biomedical technologies cluster of SKOLKOVO Innovation Center.

The cluster's priorities are aimed at supporting and implementing projects in the field of creating innovative medicines, medical diagnostic and therapeutic products, new biocompatible materials and cell technology products. Special emphasis is placed on personalized and translational medicine, biomarkers, bioinformatics, as well as devices for diagnostics and monitoring of the state of physiological parameters.

© 2020 All Rights Reserved